| アブストラクト | PURPOSE: To evaluate the overall safety of stent placement for malignant superior or inferior vena cava (SVC/IVC) syndrome by assessing adverse events in a nationwide multicenter population. METHODS: We conducted a retrospective cohort study using the Japanese Diagnosis Procedure Combination nationwide inpatient database. Patients who underwent stent placement for malignant superior or inferior vena cava (SVC/IVC) syndrome between April 2019 and March 2023 were included. The primary endpoint was the overall incidence of adverse events, which were identified using International Classification of Diseases, 10th Revision codes. Secondary evaluations included patient characteristics, underlying malignancies, therapeutic interventions, 7-day mortality after stent placement, 30-day in-hospital mortality after admission, and comparisons between the SVC and IVC groups. RESULTS: This nationwide study included 301 patients from 137 hospitals, of whom 187 underwent SVC stenting, and 114 underwent IVC stenting. Overall, 34 adverse events occurred in 32 patients (10.6%). Red blood cell transfusion was required in 10 patients (3.3%), but no invasive treatment, including embolization, was required. Seven-day mortality after stenting was 5.0%, and 30-day in-hospital mortality after admission was 11.6%. In comparisons between the SVC and IVC groups, respiratory failure was more common after SVC stenting, whereas other adverse events and mortality were comparable between groups. Lung tumors predominated in SVC cases and liver tumors in IVC cases; multiple stents were used more frequently in IVC cases. CONCLUSION: Stent placement for malignant vena cava obstruction demonstrated an overall complication rate of 10.6% with no serious adverse events requiring invasive intervention. |
|---|
| 組織名 | Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1,;Tsukiji, Chuo-ku, Tokyo, 1040045, Japan. mizukiozawa0717@gmail.com.;Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.;Division of Health Services Research, Institute for Cancer Control, National;Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.;Institute of Clinical Epidemiology (iCE), Showa Medical University, Tokyo, Japan.;Department of Health Policy and Informatics, Graduate School of Medical and;Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.;Department of Clinical Data Management and Research, Clinical Research Center,;National Hospital Organization Headquarters, Tokyo, Japan.;Department of Real-World Evidence, The University of Tokyo, Tokyo, Japan. |
|---|
